anti brg1 13 2002  (EpiCypher)


Bioz Verified Symbol EpiCypher is a verified supplier
Bioz Manufacturer Symbol EpiCypher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    EpiCypher anti brg1 13 2002
    (A-B) Heatmaps show <t>BRG1</t> localization using (A) ChIP-seq or (B) CUT&RUN in wild type (WT) and two AT-hook deletion mutants (dAT1, dAT2) that are unique to naïve and primed cells or in common for both. (C) Pie charts show the genome-wide distribution of BRG1 using ChIP-seq (left) and CUT&RUN (right). (D) The localization of a significant number of BRG1 sites detected by ChIP-seq are not affected by loss of the AT-hook of BRG1. (E) In contrast a large group of BRG1 binding sites detected by CUT&RUN are lost when the AT-hook is absent. Signals are sorted based on WT in each group; N represents the total number of peaks.
    Anti Brg1 13 2002, supplied by EpiCypher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti brg1 13 2002/product/EpiCypher
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti brg1 13 2002 - by Bioz Stars, 2024-05
    86/100 stars

    Images

    1) Product Images from "An RNA binding module of SWI/SNF is required for activation of cell-type specific enhancers and super-enhancers in early development"

    Article Title: An RNA binding module of SWI/SNF is required for activation of cell-type specific enhancers and super-enhancers in early development

    Journal: bioRxiv

    doi: 10.1101/2022.09.06.506785

    (A-B) Heatmaps show BRG1 localization using (A) ChIP-seq or (B) CUT&RUN in wild type (WT) and two AT-hook deletion mutants (dAT1, dAT2) that are unique to naïve and primed cells or in common for both. (C) Pie charts show the genome-wide distribution of BRG1 using ChIP-seq (left) and CUT&RUN (right). (D) The localization of a significant number of BRG1 sites detected by ChIP-seq are not affected by loss of the AT-hook of BRG1. (E) In contrast a large group of BRG1 binding sites detected by CUT&RUN are lost when the AT-hook is absent. Signals are sorted based on WT in each group; N represents the total number of peaks.
    Figure Legend Snippet: (A-B) Heatmaps show BRG1 localization using (A) ChIP-seq or (B) CUT&RUN in wild type (WT) and two AT-hook deletion mutants (dAT1, dAT2) that are unique to naïve and primed cells or in common for both. (C) Pie charts show the genome-wide distribution of BRG1 using ChIP-seq (left) and CUT&RUN (right). (D) The localization of a significant number of BRG1 sites detected by ChIP-seq are not affected by loss of the AT-hook of BRG1. (E) In contrast a large group of BRG1 binding sites detected by CUT&RUN are lost when the AT-hook is absent. Signals are sorted based on WT in each group; N represents the total number of peaks.

    Techniques Used: ChIP-sequencing, Genome Wide, Binding Assay

    (A) The heatmap shows the regions where BRG1 (blue) and H3K27ac (red) overlap in a cell-type specific manner in naïve (upper panel) and primed (lower panel) cells for wild type (WT) and two independent clones that lack the AT-hook (dAT1 and dAT2). (B) MLL3/4 localization at cis-regions that are AT-hook dependent in navie and primed states. (C-D) The localization of BRG1(blue), H3K27ac (red), and MLL3/4 (green) in wild type and AT-hook deletion mutants at BRG1, MLL3/4 and H3K27ac co-localized (C) and MLL3/4-H3K27ac colocalized (D) in naïve and primed states; number of sites corresponds to those sets shown in Figure S2J.
    Figure Legend Snippet: (A) The heatmap shows the regions where BRG1 (blue) and H3K27ac (red) overlap in a cell-type specific manner in naïve (upper panel) and primed (lower panel) cells for wild type (WT) and two independent clones that lack the AT-hook (dAT1 and dAT2). (B) MLL3/4 localization at cis-regions that are AT-hook dependent in navie and primed states. (C-D) The localization of BRG1(blue), H3K27ac (red), and MLL3/4 (green) in wild type and AT-hook deletion mutants at BRG1, MLL3/4 and H3K27ac co-localized (C) and MLL3/4-H3K27ac colocalized (D) in naïve and primed states; number of sites corresponds to those sets shown in Figure S2J.

    Techniques Used: Clone Assay

    (A-B) Heatmaps of all H3K4me1 (green) peaks detected by CUT&RUN for wild type and AT hook deletion mutants in naïve (A) and primed (B) cells are shown. (C-D) The heatmaps shows the extent which MLL3/4 (red) and H3K4me1 (green) overlap in naïve (C) and primed (D) cells in cis-regulatory regions and their dependency on the AT-hook of BRG1. (E) Heatmaps of H3K4me1 (green), H3K27ac (red) and BRG1 (blue) are shown for those regions where BRG1 and H3K27ac co-localize in only naïve or primed cells.
    Figure Legend Snippet: (A-B) Heatmaps of all H3K4me1 (green) peaks detected by CUT&RUN for wild type and AT hook deletion mutants in naïve (A) and primed (B) cells are shown. (C-D) The heatmaps shows the extent which MLL3/4 (red) and H3K4me1 (green) overlap in naïve (C) and primed (D) cells in cis-regulatory regions and their dependency on the AT-hook of BRG1. (E) Heatmaps of H3K4me1 (green), H3K27ac (red) and BRG1 (blue) are shown for those regions where BRG1 and H3K27ac co-localize in only naïve or primed cells.

    Techniques Used:

    (A) Venn diagram shows naïve and primed specific intronic-intergenic ATAC-seq peak. (B) Heatmap showing SMARCA4 localization (blue), ATAC-signals (grey), and active enhancer histone marks (H3K27ac [red], and H3K4me1 [green]) at naïve (top) and primed (bottom) specific intronic-intergenic ATAC-seq peaks. ChIP-seq signals are sorted based on WT SMARCA4 in each condition. (C ) Heatmap showing ATAC signals in the two independent clones of the AT-hook mutant in naïve (top) and primed (bottom) states versus WT. ATAC signals are sorted based on WT. (D ) Heatmap shows the ATAC-signals for WT and dAT-mutants in naïve (top) and primed (bottom) conditions that are unaltered; N represents the number of intronic-intergenic ATAC-seq peaks in each category. (E) Heatmap showing the pluripotency and epiblast specific (EpiSC) specific transcription factors (TFs) motif enrichment between AT-hook dependent -vs.-AT-hook independent ATAC-seq intronic-intergenic peaks in naïve and primed states. (F) DNA footprinting shows loss of primed/EpiSC specific TF Zic3 (left panel) and pluripotency TFs O ct4- S ox2- T cf- N anog (right panel) binding in the AT-hook deletion mutants.
    Figure Legend Snippet: (A) Venn diagram shows naïve and primed specific intronic-intergenic ATAC-seq peak. (B) Heatmap showing SMARCA4 localization (blue), ATAC-signals (grey), and active enhancer histone marks (H3K27ac [red], and H3K4me1 [green]) at naïve (top) and primed (bottom) specific intronic-intergenic ATAC-seq peaks. ChIP-seq signals are sorted based on WT SMARCA4 in each condition. (C ) Heatmap showing ATAC signals in the two independent clones of the AT-hook mutant in naïve (top) and primed (bottom) states versus WT. ATAC signals are sorted based on WT. (D ) Heatmap shows the ATAC-signals for WT and dAT-mutants in naïve (top) and primed (bottom) conditions that are unaltered; N represents the number of intronic-intergenic ATAC-seq peaks in each category. (E) Heatmap showing the pluripotency and epiblast specific (EpiSC) specific transcription factors (TFs) motif enrichment between AT-hook dependent -vs.-AT-hook independent ATAC-seq intronic-intergenic peaks in naïve and primed states. (F) DNA footprinting shows loss of primed/EpiSC specific TF Zic3 (left panel) and pluripotency TFs O ct4- S ox2- T cf- N anog (right panel) binding in the AT-hook deletion mutants.

    Techniques Used: ChIP-sequencing, Clone Assay, Mutagenesis, DNA Footprinting, Binding Assay

    (A) The heatmaps show WT Med1 localization in naïve (left), primed (middle), and shared (right) peaks. (B) Bargraph showing genome wide distribution of Med1 bindings. (C) Med1 was used to identify stage specific super-enahncers by ROSE. (D) Venn diagram showing the number of naïve, primed and shared Med1 super-enahncers. (E) Venn diagram showing number of Med1 super-enhancers overlapped with stage-specific AT-dep MLL3/4, Brg1-H3K27ac, and Brg1-H3K27ac-MLL3/4+MLL3/4-H3K3K27ac enhancers. (F) Bargraph showing the percentage of AT-hook dependent differential genes (Pausing) that are within 50kb, 100kb, 250kb, 500kb, 750kb, and 1Mb distance from Med1 naïve and primed specific super-enhancers.
    Figure Legend Snippet: (A) The heatmaps show WT Med1 localization in naïve (left), primed (middle), and shared (right) peaks. (B) Bargraph showing genome wide distribution of Med1 bindings. (C) Med1 was used to identify stage specific super-enahncers by ROSE. (D) Venn diagram showing the number of naïve, primed and shared Med1 super-enahncers. (E) Venn diagram showing number of Med1 super-enhancers overlapped with stage-specific AT-dep MLL3/4, Brg1-H3K27ac, and Brg1-H3K27ac-MLL3/4+MLL3/4-H3K3K27ac enhancers. (F) Bargraph showing the percentage of AT-hook dependent differential genes (Pausing) that are within 50kb, 100kb, 250kb, 500kb, 750kb, and 1Mb distance from Med1 naïve and primed specific super-enhancers.

    Techniques Used: Genome Wide

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    EpiCypher anti brg1 13 2002
    (A-B) Heatmaps show <t>BRG1</t> localization using (A) ChIP-seq or (B) CUT&RUN in wild type (WT) and two AT-hook deletion mutants (dAT1, dAT2) that are unique to naïve and primed cells or in common for both. (C) Pie charts show the genome-wide distribution of BRG1 using ChIP-seq (left) and CUT&RUN (right). (D) The localization of a significant number of BRG1 sites detected by ChIP-seq are not affected by loss of the AT-hook of BRG1. (E) In contrast a large group of BRG1 binding sites detected by CUT&RUN are lost when the AT-hook is absent. Signals are sorted based on WT in each group; N represents the total number of peaks.
    Anti Brg1 13 2002, supplied by EpiCypher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti brg1 13 2002/product/EpiCypher
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti brg1 13 2002 - by Bioz Stars, 2024-05
    86/100 stars
      Buy from Supplier

    Image Search Results


    (A-B) Heatmaps show BRG1 localization using (A) ChIP-seq or (B) CUT&RUN in wild type (WT) and two AT-hook deletion mutants (dAT1, dAT2) that are unique to naïve and primed cells or in common for both. (C) Pie charts show the genome-wide distribution of BRG1 using ChIP-seq (left) and CUT&RUN (right). (D) The localization of a significant number of BRG1 sites detected by ChIP-seq are not affected by loss of the AT-hook of BRG1. (E) In contrast a large group of BRG1 binding sites detected by CUT&RUN are lost when the AT-hook is absent. Signals are sorted based on WT in each group; N represents the total number of peaks.

    Journal: bioRxiv

    Article Title: An RNA binding module of SWI/SNF is required for activation of cell-type specific enhancers and super-enhancers in early development

    doi: 10.1101/2022.09.06.506785

    Figure Lengend Snippet: (A-B) Heatmaps show BRG1 localization using (A) ChIP-seq or (B) CUT&RUN in wild type (WT) and two AT-hook deletion mutants (dAT1, dAT2) that are unique to naïve and primed cells or in common for both. (C) Pie charts show the genome-wide distribution of BRG1 using ChIP-seq (left) and CUT&RUN (right). (D) The localization of a significant number of BRG1 sites detected by ChIP-seq are not affected by loss of the AT-hook of BRG1. (E) In contrast a large group of BRG1 binding sites detected by CUT&RUN are lost when the AT-hook is absent. Signals are sorted based on WT in each group; N represents the total number of peaks.

    Article Snippet: Briefly, 5 × 10 5 cells were captured with Concanavalin A, permeabilized using 0.01% digitonin and incubated with 0.5 μg antibody (anti-MLL3/4 serum [kind gift from Dr. Joanna Wysocka]/ anti-BRG1[#13-2002]/ anti-H3K27ac [#13-0045]/ anti-H3K4me1 [#13-0040; Epicypher]/ IgG [# 13-0042; Epicypher]) in 50 μL antibody buffer (20 mM HEPES at pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 1x protease inhibitor cocktails [EDTA-free tablet; Roche], 2 mM EDTA, 0.01% digitonin) for overnight.

    Techniques: ChIP-sequencing, Genome Wide, Binding Assay

    (A) The heatmap shows the regions where BRG1 (blue) and H3K27ac (red) overlap in a cell-type specific manner in naïve (upper panel) and primed (lower panel) cells for wild type (WT) and two independent clones that lack the AT-hook (dAT1 and dAT2). (B) MLL3/4 localization at cis-regions that are AT-hook dependent in navie and primed states. (C-D) The localization of BRG1(blue), H3K27ac (red), and MLL3/4 (green) in wild type and AT-hook deletion mutants at BRG1, MLL3/4 and H3K27ac co-localized (C) and MLL3/4-H3K27ac colocalized (D) in naïve and primed states; number of sites corresponds to those sets shown in Figure S2J.

    Journal: bioRxiv

    Article Title: An RNA binding module of SWI/SNF is required for activation of cell-type specific enhancers and super-enhancers in early development

    doi: 10.1101/2022.09.06.506785

    Figure Lengend Snippet: (A) The heatmap shows the regions where BRG1 (blue) and H3K27ac (red) overlap in a cell-type specific manner in naïve (upper panel) and primed (lower panel) cells for wild type (WT) and two independent clones that lack the AT-hook (dAT1 and dAT2). (B) MLL3/4 localization at cis-regions that are AT-hook dependent in navie and primed states. (C-D) The localization of BRG1(blue), H3K27ac (red), and MLL3/4 (green) in wild type and AT-hook deletion mutants at BRG1, MLL3/4 and H3K27ac co-localized (C) and MLL3/4-H3K27ac colocalized (D) in naïve and primed states; number of sites corresponds to those sets shown in Figure S2J.

    Article Snippet: Briefly, 5 × 10 5 cells were captured with Concanavalin A, permeabilized using 0.01% digitonin and incubated with 0.5 μg antibody (anti-MLL3/4 serum [kind gift from Dr. Joanna Wysocka]/ anti-BRG1[#13-2002]/ anti-H3K27ac [#13-0045]/ anti-H3K4me1 [#13-0040; Epicypher]/ IgG [# 13-0042; Epicypher]) in 50 μL antibody buffer (20 mM HEPES at pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 1x protease inhibitor cocktails [EDTA-free tablet; Roche], 2 mM EDTA, 0.01% digitonin) for overnight.

    Techniques: Clone Assay

    (A-B) Heatmaps of all H3K4me1 (green) peaks detected by CUT&RUN for wild type and AT hook deletion mutants in naïve (A) and primed (B) cells are shown. (C-D) The heatmaps shows the extent which MLL3/4 (red) and H3K4me1 (green) overlap in naïve (C) and primed (D) cells in cis-regulatory regions and their dependency on the AT-hook of BRG1. (E) Heatmaps of H3K4me1 (green), H3K27ac (red) and BRG1 (blue) are shown for those regions where BRG1 and H3K27ac co-localize in only naïve or primed cells.

    Journal: bioRxiv

    Article Title: An RNA binding module of SWI/SNF is required for activation of cell-type specific enhancers and super-enhancers in early development

    doi: 10.1101/2022.09.06.506785

    Figure Lengend Snippet: (A-B) Heatmaps of all H3K4me1 (green) peaks detected by CUT&RUN for wild type and AT hook deletion mutants in naïve (A) and primed (B) cells are shown. (C-D) The heatmaps shows the extent which MLL3/4 (red) and H3K4me1 (green) overlap in naïve (C) and primed (D) cells in cis-regulatory regions and their dependency on the AT-hook of BRG1. (E) Heatmaps of H3K4me1 (green), H3K27ac (red) and BRG1 (blue) are shown for those regions where BRG1 and H3K27ac co-localize in only naïve or primed cells.

    Article Snippet: Briefly, 5 × 10 5 cells were captured with Concanavalin A, permeabilized using 0.01% digitonin and incubated with 0.5 μg antibody (anti-MLL3/4 serum [kind gift from Dr. Joanna Wysocka]/ anti-BRG1[#13-2002]/ anti-H3K27ac [#13-0045]/ anti-H3K4me1 [#13-0040; Epicypher]/ IgG [# 13-0042; Epicypher]) in 50 μL antibody buffer (20 mM HEPES at pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 1x protease inhibitor cocktails [EDTA-free tablet; Roche], 2 mM EDTA, 0.01% digitonin) for overnight.

    Techniques:

    (A) Venn diagram shows naïve and primed specific intronic-intergenic ATAC-seq peak. (B) Heatmap showing SMARCA4 localization (blue), ATAC-signals (grey), and active enhancer histone marks (H3K27ac [red], and H3K4me1 [green]) at naïve (top) and primed (bottom) specific intronic-intergenic ATAC-seq peaks. ChIP-seq signals are sorted based on WT SMARCA4 in each condition. (C ) Heatmap showing ATAC signals in the two independent clones of the AT-hook mutant in naïve (top) and primed (bottom) states versus WT. ATAC signals are sorted based on WT. (D ) Heatmap shows the ATAC-signals for WT and dAT-mutants in naïve (top) and primed (bottom) conditions that are unaltered; N represents the number of intronic-intergenic ATAC-seq peaks in each category. (E) Heatmap showing the pluripotency and epiblast specific (EpiSC) specific transcription factors (TFs) motif enrichment between AT-hook dependent -vs.-AT-hook independent ATAC-seq intronic-intergenic peaks in naïve and primed states. (F) DNA footprinting shows loss of primed/EpiSC specific TF Zic3 (left panel) and pluripotency TFs O ct4- S ox2- T cf- N anog (right panel) binding in the AT-hook deletion mutants.

    Journal: bioRxiv

    Article Title: An RNA binding module of SWI/SNF is required for activation of cell-type specific enhancers and super-enhancers in early development

    doi: 10.1101/2022.09.06.506785

    Figure Lengend Snippet: (A) Venn diagram shows naïve and primed specific intronic-intergenic ATAC-seq peak. (B) Heatmap showing SMARCA4 localization (blue), ATAC-signals (grey), and active enhancer histone marks (H3K27ac [red], and H3K4me1 [green]) at naïve (top) and primed (bottom) specific intronic-intergenic ATAC-seq peaks. ChIP-seq signals are sorted based on WT SMARCA4 in each condition. (C ) Heatmap showing ATAC signals in the two independent clones of the AT-hook mutant in naïve (top) and primed (bottom) states versus WT. ATAC signals are sorted based on WT. (D ) Heatmap shows the ATAC-signals for WT and dAT-mutants in naïve (top) and primed (bottom) conditions that are unaltered; N represents the number of intronic-intergenic ATAC-seq peaks in each category. (E) Heatmap showing the pluripotency and epiblast specific (EpiSC) specific transcription factors (TFs) motif enrichment between AT-hook dependent -vs.-AT-hook independent ATAC-seq intronic-intergenic peaks in naïve and primed states. (F) DNA footprinting shows loss of primed/EpiSC specific TF Zic3 (left panel) and pluripotency TFs O ct4- S ox2- T cf- N anog (right panel) binding in the AT-hook deletion mutants.

    Article Snippet: Briefly, 5 × 10 5 cells were captured with Concanavalin A, permeabilized using 0.01% digitonin and incubated with 0.5 μg antibody (anti-MLL3/4 serum [kind gift from Dr. Joanna Wysocka]/ anti-BRG1[#13-2002]/ anti-H3K27ac [#13-0045]/ anti-H3K4me1 [#13-0040; Epicypher]/ IgG [# 13-0042; Epicypher]) in 50 μL antibody buffer (20 mM HEPES at pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 1x protease inhibitor cocktails [EDTA-free tablet; Roche], 2 mM EDTA, 0.01% digitonin) for overnight.

    Techniques: ChIP-sequencing, Clone Assay, Mutagenesis, DNA Footprinting, Binding Assay

    (A) The heatmaps show WT Med1 localization in naïve (left), primed (middle), and shared (right) peaks. (B) Bargraph showing genome wide distribution of Med1 bindings. (C) Med1 was used to identify stage specific super-enahncers by ROSE. (D) Venn diagram showing the number of naïve, primed and shared Med1 super-enahncers. (E) Venn diagram showing number of Med1 super-enhancers overlapped with stage-specific AT-dep MLL3/4, Brg1-H3K27ac, and Brg1-H3K27ac-MLL3/4+MLL3/4-H3K3K27ac enhancers. (F) Bargraph showing the percentage of AT-hook dependent differential genes (Pausing) that are within 50kb, 100kb, 250kb, 500kb, 750kb, and 1Mb distance from Med1 naïve and primed specific super-enhancers.

    Journal: bioRxiv

    Article Title: An RNA binding module of SWI/SNF is required for activation of cell-type specific enhancers and super-enhancers in early development

    doi: 10.1101/2022.09.06.506785

    Figure Lengend Snippet: (A) The heatmaps show WT Med1 localization in naïve (left), primed (middle), and shared (right) peaks. (B) Bargraph showing genome wide distribution of Med1 bindings. (C) Med1 was used to identify stage specific super-enahncers by ROSE. (D) Venn diagram showing the number of naïve, primed and shared Med1 super-enahncers. (E) Venn diagram showing number of Med1 super-enhancers overlapped with stage-specific AT-dep MLL3/4, Brg1-H3K27ac, and Brg1-H3K27ac-MLL3/4+MLL3/4-H3K3K27ac enhancers. (F) Bargraph showing the percentage of AT-hook dependent differential genes (Pausing) that are within 50kb, 100kb, 250kb, 500kb, 750kb, and 1Mb distance from Med1 naïve and primed specific super-enhancers.

    Article Snippet: Briefly, 5 × 10 5 cells were captured with Concanavalin A, permeabilized using 0.01% digitonin and incubated with 0.5 μg antibody (anti-MLL3/4 serum [kind gift from Dr. Joanna Wysocka]/ anti-BRG1[#13-2002]/ anti-H3K27ac [#13-0045]/ anti-H3K4me1 [#13-0040; Epicypher]/ IgG [# 13-0042; Epicypher]) in 50 μL antibody buffer (20 mM HEPES at pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 1x protease inhibitor cocktails [EDTA-free tablet; Roche], 2 mM EDTA, 0.01% digitonin) for overnight.

    Techniques: Genome Wide